Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 4/20 | 0.68 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SCN4A | P35499 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31327779 | 1.00 | NT5E (0.68) | NT5ECCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL10508587 | 0.90 | NT5E (0.55) | NT5ECCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL9493468 | 0.90 | NT5E (0.64) | NT5ECCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL9493482 | 0.90 | NT5E (0.55) | NT5ECCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL14690650 | 0.86 | NT5E (0.50) | NT5ECCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL3826784 | 0.86 | NT5E (0.54) | NT5EKDM4EBACE1EPHX2SCN4A | |
| SCHEMBL30492143 | 0.84 | NT5E (0.70) | NT5EDHODHKDM4EIGF1RLMNA | |
| SCHEMBL2709700 | 0.84 | NT5E (0.70) | NT5EDHODHKDM4EIGF1RLMNA | |
| SCHEMBL5101813 | 0.83 | LMNA (0.62) | NT5ECCNE2CCNA2CCNE1CDK2 | |
| SCHEMBL1536339 | 0.82 | NT5E (0.70) | NT5EDHODHKDM4EIGF1RLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084063-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION | 2025-03-13 | — | — | US | disclosed |
| WO-2025042736-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | INCYTE CORPORATION (US) | 2025-02-27 | — | — | WO | disclosed |
| EP-1930319-B1 | Proline derivatives and use thereof as drugs | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-05-02 | — | — | EP | disclosed |
| EP-1308439-B1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | MITSUBISHI TANABE PHARMA CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1950199-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-07-30 | — | — | EP | disclosed |
| EP-1930319-A1 | Proline derivatives and use thereof as drugs | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-06-11 | — | — | EP | disclosed |
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2006-08-03 | — | — | US | disclosed |
| US-7074794-B2 | Proline derivatives and the use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-07-11 | — | — | US | disclosed |
| US-7060722-B2 | Proline derivatives and use thereof as drugs | MITSUBISHI PHARMA CORPORATION (JP) | 2006-06-13 | — | — | US | disclosed |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | KITAJIMA HIROSHI | 2005-11-03 | — | — | US | disclosed |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-06-03 | — | — | US | disclosed |
| EP-1308439-A1 | PROLINE DERIVATIVES AND USE THEREOF AS DRUGS | WELFIDE CORPORATION (JP) | 2003-05-07 | — | — | EP | disclosed |
| EP-0111329-B1 | FLUOROMETHYL QUINOLINE DERIVATIVES AND THEIR PREPARATION | ALKALOIDA VEGYESZETI GYAR (HU) | 1989-03-15 | — | — | EP | disclosed |
| US-4659834-A | Process for the preparation of fluoromethyl-quinoline derivatives | ALKALOIDA VEGYESZETI GYAR (HU) | 1987-04-21 | — | — | US | disclosed |
| EP-0049776-B1 | 4-QUINOLINE METHANE DERIVATIVES, THEIR PREPARATION AND THEIR USE IN THE PREPARATION OF SUBSTANCES WITH A PHARMACOLOGICAL ACTIVITY | BASF Aktiengesellschaft (DE) | 1985-07-31 | — | — | EP | disclosed |
| EP-0111329-A1 | Fluoromethyl quinoline derivatives and their preparation | ALKALOIDA VEGYESZETI GYAR (HU) | 1984-06-20 | — | — | EP | disclosed |
| EP-0049776-A2 | 4-Quinoline methane derivatives, their preparation and their use in the preparation of substances with a pharmacological activity | BASF Aktiengesellschaft (DE) | 1982-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173056-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | NT5E 1422/4885CCNE2 2286/4885CCNA2 3036/4885 |
| US-20050245538-A1 | Proline derivatives and use thereof as drugs | DPP4, DPP3, DPP7 | NT5E 1422/4885CCNE2 2286/4885CCNA2 3036/4885 |
| US-20040106655-A1 | Proline derivatives and the use thereof as drugs | DPP4, DPP3, DPP7 | NT5E 1718/4885CCNE2 2822/4885CCNA2 2944/4885 |
| US-20250084063-A1 | BICYCLIC HETEROCYCLES AS MRGPRX2 ANTAGONISTS | MRGPRX2, MRGPRX1, MRGPRX4 | NT5E 2695/4885CCNE2 3265/4885CCNA2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.